Les astrocytes sont des partenaires clés des neurones. Dans l’hippocampe, et tout particulièrement au niveau des synapses CA3-CA1, en libérant la D-sérine, ces cellules gliales régulent l’activité des récepteurs glutamatergiques de type N-methyl-D-aspartate (NMDA) et de ce fait la mémoire synaptique, aussi connue sous le nom de plasticité synaptique à long terme. Cependant, le signal synaptique à l’origine de la libération de la D-sérine par les astrocytes reste à ce jour méconnu. De par des données rapportées dans la littérature nous nous sommes tout particulièrement intéressés aux récepteurs astrocytaires aux ephrins de type B3 (EphB3) et aux endocannabinoïdes de type 1 (CB1). Pour ce faire nous avons principalement utilisé une approche électrophysiologique sur des tranches aiguës d’hippocampe de souris adulte. Dans une première étude, nos données indiquent que l’activation des récepteurs EphB3 augmente la présence de D-sérine synaptique et en conséquence l’activité des récepteurs NMDA synaptiques. A l’inverse, leur inhibition diminue à la fois l’activité des récepteurs NMDA synaptiques et la potentialisation à long-terme qui en dépend (LTP ; une forme de plasticité synaptique à long terme). L’interaction EphB3-ephrinB3 contrôle donc la LTP en contrôlant la disponibilité en D-sérine synaptique. Dans une seconde étude, nous avons utilisé un modèle transgénique permettant d’inhiber l’expression des récepteurs CB1 astrocytaires (souris GFAP-CB1-KO). Nous avons découvert que la suppression de ces récepteurs diminue la disponibilité en D-sérine synaptique. De plus, nos travaux montrent que les récepteurs CB1 astrocytaires sont nécessaires à l’induction de la LTP via la D-serine. En conclusion, ces travaux de Thèse révèlent que les récepteurs astrocytaires EphB3 et CB1 régulent les fonctions dépendantes des récepteurs NMDA via le contrôle qu’ils exercent sur la disponibilité en D-sérine. / Astrocytes are key partners of neurons. In the hippocampus, and more particularly at CA3-CA1 synapses, by releasing D-serine, these glial cells regulate the activity of synaptic Nmethyl-D-aspartate (NMDA) receptors and thus synaptic memory, also known as long-term synaptic plasticity. Yet, the synaptic signal inducing D-serine release by astrocytes is still unknown. Based on interesting data from the literature we have investigated the role of the astrocytic receptors for ephrinB3 (EphB3) and endocannabinoids (CB1). To this end we used electrophysiological approaches on acute hippocampal slices of adult mice. In a first study, our data indicate on one hand that the activation of EphB3 receptors increases synaptic D-serine availability and in consequences the activity of synaptic NMDA receptor activity. On the other hand, inhibition of EphB3 receptors induces a decrease of synaptic NMDA receptor activity as well as the induction of the long-term potentiation (LTP; a form of long-term plasticity). Thus, EphB3-ephrinB3 interaction controls LTP induction through the availability of synaptic D-serine. In a second study, we used a transgenic model allowing the inhibition of CB1 receptors expression in astrocytes (GFAP-CB1-KO mice). We discovered that their deletion reduced synaptic D-serine availability. Our work shows that astrocytic CB1 receptors are necessary for LTP induction via this D-serine. All together, this PhD work reveals that astrocytic EphB3 and CB1 receptors regulate synaptic NMDA receptor functions through the control of D-serine availability.

Le cortex cérébral constitue l’une des structures les plus évoluées et complexes de notre cerveau. Sa surface est divisée en de nombreuses aires fonctionnelles. La mise en place des aires corticales dépend à la fois de facteurs intrinsèques comme la sécrétion de morphogènes ou l’expression en gradient de différents facteurs de transcription, mais elle dépend aussi de facteurs extrinsèques au cortex, en particulier l'innervation par le thalamus. Les ephrines et leurs récepteurs Eph constituent une famille multigénique de facteurs de signalisation impliqués dans divers événements clé du développement cortical où ils sont exprimés selon des profils spatio-temporels complexes. Aux stades tardifs du développement, EphA7 et l’ephrine-A5 sont exprimés en gradients complémentaires au sein de chaque territoire des aires présomptives, constituant ainsi les marqueurs les plus précoces de ces aires corticales. Par la combinaison d’approches in-vitro utilisant la technique d’électroporation focale de tranches corticales embryonnaires, puis in-vivo en utilisant la technique de transgénèse d’addition, nous avons identifié une séquence régulatrice de EphA7 appelée pA7, capable de mimer l’expression endogène de EphA7 au sein du télencéphale dorsal en développement. La lignée de souris pA7-GFP ainsi générée exprime la GFP spécifiquement au sein du télencéphale dorsal durant les stades précoces. Aux stades périnataux cette expression se régionalise au sein de la plaque corticale de chacune des aires présomptives selon des gradients récapitulant ceux observés pour EphA7. Nous avons ensuite purifié des neurones exprimant différents niveaux d’EphA7 par la technique de FACS «Fluorescence-Activated Cell Sorting » et l’analyse de leur transcriptome nous a permis de trouver un grand nombre de gènes différentiellement exprimés. Tous ceux testés par la technique d’hybridation in situ sont exprimés selon un gradient latéral fort et médial faible dans le cortex pariétal, similaire à celui d’EphA7. L’examination de leur profil au sein de cortex de souris dépourvus d’afférences thalamiques, nous a permis de conclure que l’expression de ces gènes incluant EphA7 s’établit indépendamment de celles-ci. Ainsi, notre étude a permis d'identifier un répertoire de gènes neuronaux, pouvant agir en amont ou en combinaison avec EphA7 pour contrôler les facteurs intrinsèques essentiels à l’établissement des aires corticales./ The cerebral cortex is subdivided into distinct cortical areas characterized by specific patterns of gene expression and neuronal connectivity. The patterning of cortical areas is thought to be controlled by a combination of intrinsic factors that are expressed in the cortex, and external signals such as inputs from the thalamus. EphA7 is a member of the ephrin/Eph family of guidance factors that is involved in key aspects of the development of the cortex, and is expressed in several gradients within developing cortical areas. By combining in vitro transcriptional assays and mouse transgenics, we identified a regulatory element of the EphA7 promoter, named pA7, that can recapitulate salient features of the pattern of expression of EphA7 in the developing forebrain, including gradients in the cortex. Using a mouse reporter line where GFP expression recapitulates EphA7 expression, we developed a GFP-based cell sorting procedure to isolate cortical neuron populations displaying different levels of EphA7 expression. Transcriptome analysis of these populations enabled to identify a specific array of differentially expressed genes. All genes validated further in vivo were confirmed to be expressed along distinct gradients in the developing cortical plate, similarly to EphA7. The expression of these genes was unchanged in mutant mice defective for thalamocortical projections, indicating that their graded pattern is largely intrinsic to the cortex. Our study identifies a novel repertoire of cortical neuron genes that may act upstream of, or together with EphA7, to control the intrinsic patterning of cortical areas.

No description available.

Title page, table of contents and abstract only. The complete thesis in print form is available from the University of Adelaide Library. / The ophthalmic, maxillary and mandibular axon branches of the trigeminal ganglion (TG) provide cutaneous sensory innervation to the vertebrate face, and multiple families of guidance cues amalgamate to direct the navigation of these branches. However, target tissue specific guidance cues that discriminately guide the three TG axon branches are unknown. Prior work demonstrated that EphAs and ephrin-As could discriminately direct dorsal versus ventral motor axon projections into the hindlimb. Similarly, do EphA tyrosine kinases and ephrin-A ligands discriminately guide trigeminal ganglion ophthalmic (TGop) lobe versus maxillomandibular (TGmm) axon projections into the chick embryo face? The aims of this work were two-fold: (1) to identify candidate EphA and ephrin-A molecules during TG axon guidance, and (2) to detennine the functional significance of TG axon EphA and ephrin-A signalling in vitro. This study identified EphA3, EphA4, ephrin-A2 and ephrin-A5 at stages 13, IS and 20, as putative guidance cues to TG axons. TG-EphA3 and -ephrin-A5 were identified as putative receptors to guidance cues expressed in the target fields. EphA3 receptor was differentially expressed, with the TGop lobe expressing higher levels compared to the TGmm lobe. However, ephrin-A5 transcript was not differentially expressed between the two ganglion lobes. In a substratum choice in vitro assay, ephrin-AS-Fc was found to repel approximately 50% of axons growing from stage 20 whole TG explants. This population of axons was identified to be from the TGop lobe. The in vitro data supports the contention that during facial development there may be trigeminal ganglion lobe specific guidance of TGop in comparison to TGmm peripheral sensory axonal projections to target fields coordinated through EphA3 and ephrin-A2/A5 repulsive interactions. In vitro, EphA4-Fc caused morphological changes to TG growth cones, which is likely mediated through TG ephrin-A5 reverse signaling. Furthermore, this study provided in vitro evidence that trigeminal ganglion axons were not responsive to EphA4-Fc, possibly implying that EphAs expressed in the target fields were not repulsive to ganglionic axons during pathfinding. The data suggests that EphN ephrin-A interactions may specifically guide TGop projections into the ophthalmic process similar to lateral motor axon guidance into the hindlimb. For the first time, a model of how EphN ephrin-A interactions and other families of guidance cues may act in concert to guide trigeminal ganglion axons is suggested. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1179603 / Thesis (Ph.D.) -- University of Adelaide, School of Molecular and Biomedical Science, 2005

Durant ma thèse, j’ai participé à une étude fonctionnelle qui a démontré que p120-RasGAP, une protéine appartenant à la famille GAP (GTPase-activating protein), est le médiateur cytoplasmique de l’éphrine lors de l’atténuation d’ERK1/2. Pour confirmer cela, j’ai réalisé une expérience de co-immunoprécipitation et j’ai démontré que p120-RasGAP s’associe au récepteur de l’éphrine, Eph3, quand celui-ci est activé par un ligand éphrine. Ce résultat indique fortement que les signaux FGF et éphrine convergent au niveau de Ras et qu’ils contrôlent de manière antagoniste son activité. Dès lors, j’ai analysé les autres événements de spécification cellulaire impliquant l’antagonisme FGF/éphrine. Chez l’embryon d’ascidie, le signal FGF est décrit comme inducteur du destin neural dans les cellules ectodermiques qui, en absence du signal FGF, adoptent le destin épidermique. L’induction neurale des ascidies a lieu au stade 32 cellules et se traduit par la spécification de quatre précurseurs neuraux (ERK+) parmi les 16 cellules ectodermiques. J’ai démontré que le signal éphrine/Eph/RasGAP antagonise le signal FGF pour générer une activation d’ERK1/2 de type tout ou rien parmi les cellules ectodermiques. Enfin, en collaboration avec Philip Abitua, doctorant dans le laboratoire du Dr. Mike Levine (UC Berkeley), nous démontrons que l’antagonisme entre les signaux éphrine et FGF est impliqué dans la régionalisation antéro-postérieure de la plaque neurale / During my thesis study, I was involved in functional studies to demonstrate that p120-RasGAP, a GTPase-activating-protein (GAP), is a cytoplasmic mediator of the ephrin-mediated ERK attenuation. To confirm this notion, I conducted a co-immunoprecipitation experiment and demonstrated that p120-RasGAP associates with an ephrin receptor, Eph3, when the latter is activated by an ephrin ligand in ascidian embryos. These results strongly indicate that FGF and ephrin signals converge at the level of Ras and control its activity antagonistically. Following this finding, I looked for other cell fate specification events controlled by the antagonism between ephrin and FGF signals. In ascidian embryos, FGF signals are known to induce neural fates in ectodermal cells which otherwise adopt epidermal fates. Ascidian neural induction takes place at the 32-cell stage, resulting in specification of specific four cells as ERK1/2-active neural precursors among 16 ectodermal cells. I was able to demonstrate that ephrin/Eph/RasGAP signals counterbalance FGF neural inducing signals to generate the ON-OFF response of ERK activation among the ectodermal cells. Finally, in collaboration with a PhD student in Dr. Mike Levine’s lab (UC Berkeley), the antagonism between ephrin and FGF signals plays a role in regionalisation of the neural plate along the anterior-posterior axis.

Traumatic brain injury (TBI) can cause a number of deleterious effects to the neurovascular system, including reduced cerebral blood flow (CBF), vascular regression, and ischemia, resulting in cognitive decline. Research into therapeutic targets to restore neurovascular function following injury has identified endothelial EphA4 receptor tyrosine kinase as a major regulator of vascular regrowth. The research outlined herein utilizes an endothelial-specific EphA4 knockout mouse model (KO-EphA4flf/Tie2-Cre) to determine the extent to which this receptor may influence vascular regrowth following TBI. Analysis of the colocalization and proximity of endothelial and mural cell markers (i.e. PECAM-1 and PDGFRβ, respectively) in immunohistochemically-stained brain sections demonstrates that EphA4 silencing does not seem to affect the physical association between, nor total amounts of, endothelial cells and pericytes, between genotypes by 4 days post-injury (dpi). Nevertheless, these measures demonstrate that these cell types may preferentially proliferate and/or expand into peri-lesion tissue in both KO-EphA4flf/Tie2-Cre) and WT-EphA4fl/fl mice. These data further suggest that both genotypes experience homogeneity of PECAM-1 and PDGFRβ expression between regions of the injury cavity. Gene expression analysis using mRNA samples from both genotypes reveals that KO-EphA4flf/Tie2-Cre CCI-injured mice experience increased expression of Vegfa, Flt1, and Fn (Fibronectin) compared to sham-injured condition knockouts. These results demonstrate changes in expression of angiogenic factors in the absence of early differences in patterns of vessel formation, which may underlie improved vascular regrowth, as well as outline a potential mechanism wherein the interplay between these factors and EphA4 silencing may lead to improved cognitive outcomes following TBI. / Master of Science / Every day in the United States, an average of 155 people die due to the consequences of traumatic brain injury (TBI), with many survivors suffering life-long debilitating effects, including deficits in behavior, mobility, and cognitive ability. Because of this, there is a need for researchers to identify therapeutic strategies to stimulate recovery and improve patient outcomes. Recent advancements in the field of vascular biology have identified the regrowth of the blood vessels in the brain following TBI-induced damage as an important step in the recovery process, since the resulting increases in blood flow to damaged tissue will provide oxygen and nutrients necessary to fuel recovery. The work presented in this Masters thesis follows in this vein by examining a protein receptor known as EphA4, which is found on cells within blood vessels and has been implicated in reducing the rate of vessel growth under injury conditions. By blocking the activity of EphA4, we hoped to find increased vascular regrowth following brain injury in mice. During the experiments outlined herein, it was found that there were no statistically significant differences in vessel-associated cell densities between mice with or without EphA4 activity 4 days after injury, but there were differences in the levels of proteins and/or signals associated with vessel growth. Based on these results, we conclude that removing EphA4 activity increases expression of these pro-vessel growth proteins in mouse brains following injury at these early time points, potentially leading to increased vessel growth and improved recovery over subsequent weeks following injury.

Nipah virus (NiV) and Hendra virus (HeV) have been identified as the causes of outbreaks of fatal meningitis, encephalitis, and respiratory disease in Australia, Malaysia, Bangladesh, and India from 1994 until 2004. In order to accommodate the unique genomic characteristics of NiV and HeV, a new genus within the family Paramyxoviridae was created, named Henipavirus. NiV encodes two surface glycoproteins: the attachment glycoprotein (G) binds to the cellular receptor for the virus, while the fusion glycoprotein (F) mediates membrane fusion between the virus and cell membranes. Expression of F and G in the same cell results in cell-cell fusion in transfected cell monolayers, while expression of F and G on their own in cell monolayers does not result in fusion. Co-culture of singly-transfected F and G cells also does not result in fusion. Expression of NiV G in transgenic CRFK cells results in resistance to NiV- and HeV-induced cytopathic effect. Additionally, neither NiV nor HeV nucleic acid could be detected in CRFK-NiV G that had been exposed to NiV or HeV. NiV G expression also prevents NiV F+NiV G-mediated cell-cell fusion, but does not affect cell surface expression of either virus receptor, ephrin-B2 and ephrin-B3. Chimeric glycoproteins derived from NiV G and CDV H were constructed and characterized. None of the chimeric glycoproteins were able to fuse when coexpressed with either NiV F or CDV F. Only one of the chimeric glycoproteins (H145/G458) was detected on the cell surface by immunofluorescence assay (IFA). None of the chimeric glycoproteins altered cell surface expression levels of ephrin-B2 and ephrin-B3. Finally, recombinant NiV genomes (rNiV and rNiV eGFPG) were constructed, as well as chimeric CDV genomes with NiV ORF substitutions (rCDV eGFPH NiVFG and rCDV eGFPH NiVMFG). The only chimeric virus that was generated, rCDV eGFPH NiVFG, was assessed for its release from infected cells. rCDV eGFPH NiVFG was poorly released from infected cells without a freeze-thaw cycle, but was also found to induce the cellsurface down-regulation of the viral receptors ephrin-B2 and ephrin-B3. / October 2007

Nipah virus (NiV) and Hendra virus (HeV) have been identified as the causes of outbreaks of fatal meningitis, encephalitis, and respiratory disease in Australia, Malaysia, Bangladesh, and India from 1994 until 2004. In order to accommodate the unique genomic characteristics of NiV and HeV, a new genus within the family Paramyxoviridae was created, named Henipavirus. NiV encodes two surface glycoproteins: the attachment glycoprotein (G) binds to the cellular receptor for the virus, while the fusion glycoprotein (F) mediates membrane fusion between the virus and cell membranes. Expression of F and G in the same cell results in cell-cell fusion in transfected cell monolayers, while expression of F and G on their own in cell monolayers does not result in fusion. Co-culture of singly-transfected F and G cells also does not result in fusion. Expression of NiV G in transgenic CRFK cells results in resistance to NiV- and HeV-induced cytopathic effect. Additionally, neither NiV nor HeV nucleic acid could be detected in CRFK-NiV G that had been exposed to NiV or HeV. NiV G expression also prevents NiV F+NiV G-mediated cell-cell fusion, but does not affect cell surface expression of either virus receptor, ephrin-B2 and ephrin-B3. Chimeric glycoproteins derived from NiV G and CDV H were constructed and characterized. None of the chimeric glycoproteins were able to fuse when coexpressed with either NiV F or CDV F. Only one of the chimeric glycoproteins (H145/G458) was detected on the cell surface by immunofluorescence assay (IFA). None of the chimeric glycoproteins altered cell surface expression levels of ephrin-B2 and ephrin-B3. Finally, recombinant NiV genomes (rNiV and rNiV eGFPG) were constructed, as well as chimeric CDV genomes with NiV ORF substitutions (rCDV eGFPH NiVFG and rCDV eGFPH NiVMFG). The only chimeric virus that was generated, rCDV eGFPH NiVFG, was assessed for its release from infected cells. rCDV eGFPH NiVFG was poorly released from infected cells without a freeze-thaw cycle, but was also found to induce the cellsurface down-regulation of the viral receptors ephrin-B2 and ephrin-B3.

Nipah virus (NiV) and Hendra virus (HeV) have been identified as the causes of outbreaks of fatal meningitis, encephalitis, and respiratory disease in Australia, Malaysia, Bangladesh, and India from 1994 until 2004. In order to accommodate the unique genomic characteristics of NiV and HeV, a new genus within the family Paramyxoviridae was created, named Henipavirus. NiV encodes two surface glycoproteins: the attachment glycoprotein (G) binds to the cellular receptor for the virus, while the fusion glycoprotein (F) mediates membrane fusion between the virus and cell membranes. Expression of F and G in the same cell results in cell-cell fusion in transfected cell monolayers, while expression of F and G on their own in cell monolayers does not result in fusion. Co-culture of singly-transfected F and G cells also does not result in fusion. Expression of NiV G in transgenic CRFK cells results in resistance to NiV- and HeV-induced cytopathic effect. Additionally, neither NiV nor HeV nucleic acid could be detected in CRFK-NiV G that had been exposed to NiV or HeV. NiV G expression also prevents NiV F+NiV G-mediated cell-cell fusion, but does not affect cell surface expression of either virus receptor, ephrin-B2 and ephrin-B3. Chimeric glycoproteins derived from NiV G and CDV H were constructed and characterized. None of the chimeric glycoproteins were able to fuse when coexpressed with either NiV F or CDV F. Only one of the chimeric glycoproteins (H145/G458) was detected on the cell surface by immunofluorescence assay (IFA). None of the chimeric glycoproteins altered cell surface expression levels of ephrin-B2 and ephrin-B3. Finally, recombinant NiV genomes (rNiV and rNiV eGFPG) were constructed, as well as chimeric CDV genomes with NiV ORF substitutions (rCDV eGFPH NiVFG and rCDV eGFPH NiVMFG). The only chimeric virus that was generated, rCDV eGFPH NiVFG, was assessed for its release from infected cells. rCDV eGFPH NiVFG was poorly released from infected cells without a freeze-thaw cycle, but was also found to induce the cellsurface down-regulation of the viral receptors ephrin-B2 and ephrin-B3.

EINLEITUNG Das maligne Melanom stellt aufgrund seiner frühen Metastasierung und der Resistenz gegenüber den bisher bekannten Therapieansätzen eine der aggressivsten Tumorentitäten dar. Allerdings handelt es sich beim Melanom um einen antigenen und immunogenen Tumor. Dies schürt die Hoffnung, dass durch das bessere Verständnis der Mechanismen, die der Metastasierung, aber auch der Dysregulation des Immunsystems zugrunde liegen, Rückschlüsse auf neue Therapieansätze, beispielsweise unter Einbeziehung der Immunabwehr, gezogen werden können. Darüber hinaus würde die Entwicklung von Radiotracern, die eine frühzeitige Diagnose und möglicherweise auch die Auswahl von Patienten für eine personalisierte Tumortherapie ermöglichen, die Heilungschancen des malignen Melanoms wesentlich verbessern. Das Eph-Ephrin-System wiederum stellt ein vielfältiges Zellkommunikations-System dar, das sowohl in lebenswichtige als auch in pathologische Prozesse involviert ist. Beispielsweise nehmen Eph-Rezeptoren und Ephrine Einfluss auf die gerichtete Bewegung von neuronalen, endothelialen und inflammatorischen Zellen. Zudem beeinflussen sie die Bewegung von Tumorzellen und tragen so zur Tumorprogression bei. Ausgehend von diesem Hintergrund wurde die Hypothese formuliert, dass die Eph-Ephrin-vermittelte Interaktion von Melanomzellen und Tumor-assoziierten inflammatorischen Zellen die Progression und Metastasierung des malignen Melanoms beeinflusst. Im Speziellen sollte im Rahmen der vorliegenden Arbeit geprüft werden, ob die Rezeptor-Tyrosinkinase EphB4 im Zusammenspiel mit seinem Liganden EphrinB2 die Progression und Metastasierung des malignen Melanoms fördert. Darüber hinaus sollte getestet werden, ob der Rezeptor EphB6, der ebenfalls zur Bindung von EphrinB2 fähig ist, aber über eine mutierte und damit funktionsunfähige Kinasedomäne verfügt, eine regulative Rolle übernimmt und antitumorigen wirkt. Aufbauend auf den Erkenntnissen zur Bedeutung von EphB4, EphB6 und EphrinB2 beim malignen Melanom sollten zudem verschiedene Ansätze zur Bildgebung der oben genannten Eph-Rezeptoren und Ephrine mittels PET etabliert und geprüft werden. ERGEBNISSE UND DISKUSSION Im Rahmen der vorliegenden Arbeit wurde erstmalig gezeigt, dass die Membranproteine EphB4, EphB6 und EphrinB2 bei den ausgewählten humanen Melanomzellen und den inflammatorischen Zellen exprimiert werden und somit potentielle Interaktionsmöglichkeiten dieser Zellen darstellen. Infolge der Kokultur mit HL-60(M)-Zellen, die als Modell für Tumor-assoziierte Makrophagen dienten, kam es zu einer verminderten Adhäsion und/oder Migration der Melanomzellen sowie im Falle der A375- und A2058-Melanomzellen zu einer verstärkten Sekretion des proinflammatorischen Zytokins IL-6. Aufgrund der breiten Wirkung von IL-6 ergeben sich daraus vielfältige Einflussmöglichkeiten auf das Tumormikromilieu. Diese wurden im Rahmen der vorliegenden Arbeit jedoch nicht näher charakterisiert, da erste Ergebnisse eine Beteiligung des Eph-Ephrin-Systems ausschlossen. Während die Überexpression von EphB6 keinen Einfluss auf die Metastasierungs-relevanten Eigenschaften der A375-Melanomzellen hatte, führte die erhöhte Proteinbiosynthese von EphB4 zu einer verminderten Migration der Zellen im intakten Zellverband. Des Weiteren bewirkte EphB4 eine verstärkte Adhäsion der A375-Zellen an das Extrazellularmatrix-Protein Fibronektin, wodurch die Migration dieser Melanomzellen, im Sinne einer Metastasierung, zusätzlich beeinträchtigt wird. Die erhöhte mRNA-Expression des Liganden EphrinB2 in den A375-Melanomzellen führte zu einer verminderten chemotaktischen Migration der Zellen. Um den Einfluss von EphB4 auf die Tumorprogression und Tumorangiogenese beim malignen Melanom in vivo untersuchen zu können, wurde im Rahmen der vorliegenden Arbeit ein murines Xenograft-Modell mit subkutanen A375 pIRES- bzw. A375 EphB4-Tumoren etabliert. Die Auswertung der Tumorvolumina sowie der [18F]FDG-, [18F]FMISO- und Hoechst 33342-Anreicherung in den Tumoren ergab, dass die erhöhte EphB4-Proteinbiosynthese zu tendenziell kleineren Tumoren führte. Diese waren zudem signifikant schwächer perfundiert und wiesen im Inneren größere hypoxische Areale auf als die A375 pIRES-Tumoren. Somit zeigte EphB4 neben seiner antimetastasischen Wirkung in vitro auch eine antitumorigene Wirkung in vivo, wobei letztere möglicherweise auf eine Störung der Gefäßbildung zurückzuführen ist. Da eine adäquate Blutversorgung der Tumoren für die Metastasierung von Tumorzellen von Bedeutung ist, könnte dies auch auf eine antimetastatische Wirkung in vivo hinweisen. Des Weiteren wurde im Rahmen der vorliegenden Arbeit ein neuer, 18F-markierter EphB4 Kinaseinhibitor (Verbindung [18F]2) getestet. Dieser zeigte im A375-pIRES/EphB4-Tumor-Xenograft-Modell eine geringe Tumoranreicherung, die von der EphB4-Proteinbiosynthese in den Tumoren unabhängig war. Darüber hinaus kam es zur schnellen hepatobiliären Ausscheidung von Verbindung [18F]2, was deren radiopharmazeutischer Anwendung im Wege steht. SCHLUSSFOLGERUNG UND AUSBLICK Insbesondere die erhöhte Proteinbiosynthese von EphB4 hatte im Falle der untersuchten A375-Melanomzellen zu einer verminderten Migration und zu einer erhöhten Adhäsion der Zellen geführt. Somit konnte im Rahmen der vorliegenden Arbeit gezeigt werden, dass EphB4 die Metastasierungs-relevanten Eigenschaften dieser Zellen in vitro beeinträchtigt. Darüber hinaus deuteten Untersuchungen am A375-pIRES/EphB4-Tumor-Xenograft-Modell auf eine antitumorigene Wirkung des EphB4-Rezeptors in vivo hin. Aufgrund dessen muss der anfänglich formulierten Hypothese, dass EphB4 im Zusammenspiel mit seinem Liganden EphrinB2 die Progression und Metastasierung des malignen Melanoms fördert, widersprochen werden. Eine regulative Beteiligung des Kinase-defizienten Rezeptors EphB6, der ebenfalls zur Bindung von EphrinB2 fähig ist, konnte im Rahmen der vorliegenden Arbeit nicht sicher nachgewiesen werden. Allerdings ergeben sich aufgrund der Expression der Rezeptoren EphB4 und EphB6 sowie deren Ligand EphrinB2 sowohl auf den untersuchten Melanomzellen als auch auf den verschiedenen Tumor-assoziierten inflammatorischen Zellen interessante Interaktionsmöglichkeiten dieser Zellen. Deren Einfluss auf die Progression und Metastasierung des malignen Melanoms sollte in weiterführenden Experimenten untersucht werden. Das im Rahmen der vorliegenden Arbeit etablierte A375-pIRES/EphB4-Tumor-Xenograft-Modell ermöglicht die In vivo-Charakterisierung von Radiotracer, die gegen Rezeptor-Tyrosinkinasen im Allgemeinen oder aber selektiv gegen EphB4 gerichtet sind. Da Verbindung [18F]2 eine ungünstige Pharmakokinetik zeigte, was wahrscheinlich auf die hohe Lipophilie des Radiotracers zurückzuführen ist, sollten sich zukünftige Untersuchungen mit der chemischen Modifikation dieser Verbindung beschäftigen, mit dem Ziel die Lipophilie und damit die biologische Halbwertszeit des Radiotracers zu verbessern. Zusätzlich sollte die Entwicklung von Radiotracern auf der Basis von löslichen Eph-Rezeptoren und Ephrinen (sEph bzw. sEphrin) weiter vorangetrieben werden.